Metabolic Syndrome: A Warning Sign of Liver Fibrosis

다국어 초록 (Multilingual Abstract)

None

참고문헌 (Reference)

1 Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases" 67 : 328-357, 2018

2 Nah EH, "Prevalence of liver fibrosis and associated risk factors in the Korean general population : a retrospective cross-sectional study" 11 : e046529-, 2021

3 Ginès P, "Population screening for liver fibrosis : toward early diagnosis and intervention for chronic liver diseases" 75 : 219-228, 2022

4 Marchesini G, "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome" 37 : 917-923, 2003

5 이병완 ; 이용호 ; 박철영 ; 이은정 ; 이원영 ; 김난희 ; 최경묵 ; 박근규 ; 최연경 ; 차봉수 ; 이대호 ; The Korean Diabetes Association (KDA) Fatty Liver Research Group, "Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association" 대한당뇨병학회 44 (44): 382-401, 2020

6 van Kleef LA, "Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness : the Rotterdam Study" 75 : 419-429, 2022

7 Lim S, "Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease" 32 : 500-514, 2021

8 Angulo P, "Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis" 30 : 1356-1362, 1999

9 Wong RJ, "Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis" 14 : e0220612-, 2019

10 Zhang Y, "Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population" 5 : e008204-, 2015

11 Venu Gopala Reddy Gangireddy ; Courtney Pilkerton ; Jun Xiang ; Ruben Tinajero ; Amie M. Ashcraft, "Hepatic Fibrosis and Steatosis in Metabolic Syndrome" 대한비만학회 31 (31): 61-69, 2022

12 Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes" 64 : 73-84, 2016

13 Lin H, "Epidemiology and clinical outcomes of metabolic(dysfunction)-associated fatty liver disease" 9 : 972-982, 2021

14 Mahdinloo S, "Efficient drug and gene delivery to liver fibrosis:rationale, recent advances, and perspectives" 10 : 1279-1293, 2020

15 European Association for the Study of the Liver (EASL), "EASLEASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease" 64 : 1388-1402, 2016

16 Ellis EL, "Clinical evidence for the regression of liver fibrosis" 56 : 1171-1180, 2012

17 Asrani SK, "Burden of liver diseases in the world" 70 : 151-171, 2019

18 Taylor RS, "Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease : a systematic review and meta-analysis" 158 : 1611-1625, 2020

19 Wong VW, "Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 1: definition, risk factors and assessment" 33 : 70-85, 2018

20 Eslam M, "A new definition for metabolic dysfunction-associated fatty liver disease : an international expert consensus statement" 73 : 202-209, 2020